-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitor-mediated hepatitis is a common immune-related adverse event in the treatment of programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T lymphocyte-related 4 (CTLA-4) inhibitors, or a combination of the two
.
The purpose of this real-world study is to evaluate whether immune checkpoint inhibitor-mediated hepatitis is associated with liver metastasis and clinical prognosis in patients with advanced melanoma
Immune checkpoint inhibitor-mediated hepatitis is a common immune-related adverse event in the treatment of programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T lymphocyte-related 4 (CTLA-4) inhibitors, or a combination of the two
Between May 2012 and January 2019, 2561 patients with advanced cutaneous melanoma received 3111 immune checkpoint inhibitor treatments
.
Among them, 1620 cases received PD1 inhibitor treatment, 1105 cases received ipilimumab treatment, and 386 cases received combined treatment
Between May 2012 and January 2019, 2561 patients with advanced cutaneous melanoma received 3111 immune checkpoint inhibitor treatments
Research Overview
Research OverviewAmong 1620 patients treated with PD-1 inhibition, 1048 (65%) were first-line treatment
.
Of the remaining 572 patients, 239 (15%) received ipilimumab therapy, 24 (1%) received combination therapy, and 309 (19%) received BRAF or BRAF/MEK inhibitor therapy
Among 1620 patients treated with PD-1 inhibition, 1048 (65%) were first-line treatment
Compared with non-hepatitis patients, the incidence of liver metastases in hepatitis patients was similar (32% vs.
There was no difference between median progression-free survival (PFS) and overall survival (OS) in patients with and without hepatitis (PFS: 6.
Prognostic factors of PFS and OS
Prognostic factors of PFS and OS3 patients (10%) of PD-1 inhibitor-mediated hepatitis had additional immunotherapy-related adverse events (IRAEs), and 10 patients (34%) of ipilimumab-mediated hepatitis, and combined There were 29 cases (36%) in treatment
.
The additional IRAEs mainly included 17 cases of endocrine toxicity, 13 cases of gastrointestinal toxicity, and 10 cases of skin toxicity
3 patients (10%) of PD-1 inhibitor-mediated hepatitis had additional immunotherapy-related adverse events (IRAEs), and 10 patients (34%) of ipilimumab-mediated hepatitis, and combined There were 29 cases (36%) in treatment
Other immunotherapy-related adverse events
Other immunotherapy-related adverse eventsIn summary, in the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
8%, ipilimumab was 2.
6%, and the combined treatment was 20.
7%
.
Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
In summary, in the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
8%, ipilimumab was 2.
6%, and the combined treatment was 20.
7%
.
Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
.
In the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
8%, ipilimumab was 2.
6%, and the combined treatment was 20.
7%
.
Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
.
In the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
8%, ipilimumab was 2.
6%, and the combined treatment was 20.
7%
.
Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
.
Original source:
Original source:Biewenga M, van der Kooij MK, Wouters MWJM, et al.
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
Hepatol Int.
2021 Apr;15(2):510-519.
doi: 10.
1007/ s12072-021-10151-4.
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
Hepatol Int.
2021 Apr;15(2):510-519.
doi: 10.
1007/ s12072-021-10151-4.
Leave a message here